Abstract: A pomalidomide derivative exhibiting effects better than those of pomalidomide, a preparation method therefor, and use thereof. The pomalidomide derivative has excellent binding force to cereblon, has low cytotoxicity, has a low potential for causing teratogenic side effects, can regulate the expression of TNF-? and proinflammatory cytokines, and has excellent in vivo pharmacokinetic stability even while inhibiting oxidative stress.

Abstract: The present invention relates to a novel thalidomide-based compound derivative having significantly improved water solubility due to the introduction of a sugar or sugar derivative into lenalidomide or pomalidomide, which are thalidomide-based compounds, wherein the lenalidomide or pomalidomide derivative according to the present invention has significantly increased water solubility compared to conventional lenalidomide or pomalidomide and can thus be formulated into an injection or eye drop formulation. Therefore, the lenalidomide or pomalidomide derivative can be administered in the form of a high concentration therapeutic agent to a local area, and can be easily administered in combination with a different therapeutic agent developed as an injection or eye drop formulation.

Abstract: The disclosure relates to compositions and methods of using a pomalidomide derivative that exhibits improved pharmacological effects as compared to pomalidomide for treating brain diseases. The pomalidomide derivative exhibits excellent binding to cereblon, has almost no cytotoxicity, is unlikely to cause teratogenic adverse effects, can control TNF-? expression, exhibits excellent in vivo pharmacokinetic stability while suppressing oxidative stress, ameliorates a decrease in motor function which is a symptom of Parkinson's disease, and increases tyrosine hydroxylase expression which is reduced by Parkinson's disease, and thus can be used for preventing or treating brain diseases such as Parkinson's disease.